SCHEMBL5538663

SCHEMBL5538663

CCCc1nc2cc(C)ccc2o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.62
MAPT P10636 6/20 0.62
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
RAB9A P51151 10/20 0.51
NPC1 O15118 9/20 0.51
HPGD P15428 6/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 6/20 0.51
HSD17B10 Q99714 6/20 0.51
TP53 P04637 4/20 0.51
CASP3 P42574 4/20 0.49
SENP7 Q9BQF6 4/20 0.49
SENP6 Q9GZR1 4/20 0.49
SENP8 Q96LD8 3/20 0.49
POLB P06746 1/20 0.49
GRK6 P43250 1/20 0.46
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11332226 0.91 KDM4E (0.73) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL12330340 0.90 KMT2A (0.70) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL5535594 0.86 MAPT (0.83) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL5542189 0.86 GAA (0.56) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL4904181 0.85 KDM4E (0.60) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL11328720 0.84 KDM4E (0.58) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL2245602 0.81 GRK6 (0.69) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL5538660 0.81 KMT2A (0.55) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL103074 0.81 KDM4E (0.55) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL22042899 0.81 KDM4E (0.54) KDM4EMAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDM4E 3961/4885MAPT 3962/4885MEN1 1926/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885MAPT 4117/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.